4//SEC Filing
Novartis Bioventures Ltd 4
Accession 0000925421-20-000256
CIK 0001563577other
Filed
Jun 21, 8:00 PM ET
Accepted
Jun 22, 4:52 PM ET
Size
9.6 KB
Accession
0000925421-20-000256
Insider Transaction Report
Form 4
Novartis Bioventures Ltd
10% Owner
Transactions
- Sale
Common Stock
2020-06-19$8.25/sh−1,001,312$8,260,824→ 2,467,961 total - Sale
Common Stock
2020-06-18$9.04/sh−900$8,136→ 3,469,273 total
NOVARTIS AG
10% Owner
Transactions
- Sale
Common Stock
2020-06-18$9.04/sh−900$8,136→ 3,469,273 total - Sale
Common Stock
2020-06-19$8.25/sh−1,001,312$8,260,824→ 2,467,961 total
Footnotes (3)
- [F1]Reflects sales of common stock executed in multiple transactions at prices ranging from $9.00 to $9.37. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- [F2]Novartis Bioventures Ltd is the record holder of the securities reported herein. As the indirect parent of Novartis Bioventures Ltd., Novartis AG may be deemed to share beneficial ownership of these securities.
- [F3]Reflects sales of common stock executed in multiple transactions at prices ranging from $8.25 to $9.17. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
Documents
Issuer
Galera Therapeutics, Inc.
CIK 0001563577
Entity typeother
IncorporatedBermuda
Related Parties
1- filerCIK 0001297709
Filing Metadata
- Form type
- 4
- Filed
- Jun 21, 8:00 PM ET
- Accepted
- Jun 22, 4:52 PM ET
- Size
- 9.6 KB